Comparar	O
la	O
vinflunina	O
(	O
VFL	O
)	O
con	O
el	O
docetaxel	O
en	O
pacientes	O
con	O
cáncer	O
de	O
pulmón	O
de	O
células	O
no	O
pequeñas	O
(	O
NSCLC	O
)	O
en	O
estadio	O
IIIB/IV	O
que	O
han	O
experimentado	O
un	O
fracaso	O
del	O
tratamiento	O
con	O
quimioterapia	O
de	O
primera	O
línea	O
basada	O
en	O
platino	O
.	O

Estudio	O
aleatorizado	O
,	O
multicéntrico	O
,	O
de	O
fase	O
III	O
,	O
551	O
pacientes	O
recibieron	O
320	O
mg/m	O
(	O
2	O
)	O
de	O
vinflunina	O
o	O
75	O
mg/m	O
(	O
2	O
)	O
de	O
docetaxel	O
cada	O
21	O
días	O
hasta	O
la	O
progresión	O
de	O
la	O
enfermedad	O
o	O
toxicidad	O
grave	O
.	O

El	O
punto	O
final	O
primario	O
fue	O
la	O
supervivencia	O
libre	O
de	O
progresión	O
(	O
PFS	O
)	O
.	O

El	O
análisis	O
de	O
no	O
inferioridad	O
se	O
basó	O
en	O
una	O
diferencia	O
del	O
10	O
%	O
(	O
tasas	O
de	O
error	O
de	O
tipo	O
I	O
/	O
II	O
:	O
5	O
%	O
/20	O
%	O
)	O
.	O

Los	O
puntos	O
finales	O
secundarios	O
incluyeron	O
la	O
tasa	O
de	O
respuesta	O
(	O
ORR	O
)	O
,	O
la	O
duración	O
de	O
la	O
respuesta	O
,	O
la	O
supervivencia	O
general	O
(	O
SG	O
)	O
,	O
el	O
beneficio	O
clínico	O
,	O
la	O
calidad	O
de	O
vida	O
(	O
QOL	O
)	O
y	O
la	O
seguridad	O
.	O

La	O
mediana	B-Premise-Support-5
de	I-Premise-Support-5
SLP	I-Premise-Support-5
fue	I-Premise-Support-5
de	I-Premise-Support-5
2,3	I-Premise-Support-5
meses	I-Premise-Support-5
para	I-Premise-Support-5
cada	I-Premise-Support-5
brazo	I-Premise-Support-5
(	I-Premise-Support-5
HR	I-Premise-Support-5
,	I-Premise-Support-5
1,004	I-Premise-Support-5
;	I-Premise-Support-5
IC	I-Premise-Support-5
del	I-Premise-Support-5
95	I-Premise-Support-5
%	I-Premise-Support-5
,	I-Premise-Support-5
0,841	I-Premise-Support-5
a	I-Premise-Support-5
1,199	I-Premise-Support-5
)	I-Premise-Support-5
.	I-Premise-Support-5

ORR	B-Premise-Support-4
,	I-Premise-Support-4
enfermedad	I-Premise-Support-4
estable	I-Premise-Support-4
,	I-Premise-Support-4
mediana	I-Premise-Support-4
de	I-Premise-Support-4
OS	I-Premise-Support-4
,	I-Premise-Support-4
fueron	I-Premise-Support-4
4,4	I-Premise-Support-4
%	I-Premise-Support-4
versus	I-Premise-Support-4
5,5	I-Premise-Support-4
%	I-Premise-Support-4
,	I-Premise-Support-4
36,0	I-Premise-Support-4
%	I-Premise-Support-4
versus	I-Premise-Support-4
39,6	I-Premise-Support-4
%	I-Premise-Support-4
,	I-Premise-Support-4
6,7	I-Premise-Support-4
versus	I-Premise-Support-4
7,2	I-Premise-Support-4
meses	I-Premise-Support-4
(	I-Premise-Support-4
CRI	I-Premise-Support-4
,	I-Premise-Support-4
0,973	I-Premise-Support-4
;	I-Premise-Support-4
IC	I-Premise-Support-4
del	I-Premise-Support-4
95	I-Premise-Support-4
%	I-Premise-Support-4
,	I-Premise-Support-4
0,805	I-Premise-Support-4
a	I-Premise-Support-4
1,176	I-Premise-Support-4
)	I-Premise-Support-4
,	I-Premise-Support-4
respectivamente	I-Premise-Support-4
.	I-Premise-Support-4

No	B-Premise-Support-3
hubo	I-Premise-Support-3
diferencias	I-Premise-Support-3
significativas	I-Premise-Support-3
en	I-Premise-Support-3
el	I-Premise-Support-3
beneficio	I-Premise-Support-3
para	I-Premise-Support-3
el	I-Premise-Support-3
paciente	I-Premise-Support-3
y	I-Premise-Support-3
la	I-Premise-Support-3
CdV	I-Premise-Support-3
(	I-Premise-Support-3
evaluación	I-Premise-Support-3
funcional	I-Premise-Support-3
de	I-Premise-Support-3
la	I-Premise-Support-3
terapia	I-Premise-Support-3
del	I-Premise-Support-3
cáncer	I-Premise-Support-3
de	I-Premise-Support-3
pulmón	I-Premise-Support-3
)	I-Premise-Support-3
.	I-Premise-Support-3

No	B-Premise-Support-4
se	I-Premise-Support-4
observaron	I-Premise-Support-4
eventos	I-Premise-Support-4
adversos	I-Premise-Support-4
inesperados	I-Premise-Support-4
.	I-Premise-Support-4

Grado	B-Premise-Support-2
superior	I-Premise-Support-2
a	I-Premise-Support-2
0	I-Premise-Support-2
(	I-Premise-Support-2
vinflunina	I-Premise-Support-2
frente	I-Premise-Support-2
a	I-Premise-Support-2
docetaxel	I-Premise-Support-2
)	I-Premise-Support-2
anemia	I-Premise-Support-2
(	I-Premise-Support-2
82,1	I-Premise-Support-2
%	I-Premise-Support-2
frente	I-Premise-Support-2
a	I-Premise-Support-2
79,8	I-Premise-Support-2
%	I-Premise-Support-2
)	I-Premise-Support-2
,	I-Premise-Support-2
neutropenia	I-Premise-Support-2
(	I-Premise-Support-2
49,3	I-Premise-Support-2
%	I-Premise-Support-2
frente	I-Premise-Support-2
a	I-Premise-Support-2
39,02	I-Premise-Support-2
%	I-Premise-Support-2
)	I-Premise-Support-2
,	I-Premise-Support-2
trombocitopenia	I-Premise-Support-2
(	I-Premise-Support-2
30,6	I-Premise-Support-2
%	I-Premise-Support-2
frente	I-Premise-Support-2
a	I-Premise-Support-2
14,3	I-Premise-Support-2
%	I-Premise-Support-2
)	I-Premise-Support-2
,	I-Premise-Support-2
neutropenia	I-Premise-Support-2
febril	I-Premise-Support-2
(	I-Premise-Support-2
3,3	I-Premise-Support-2
%	I-Premise-Support-2
frente	I-Premise-Support-2
a	I-Premise-Support-2
4,7	I-Premise-Support-2
%	I-Premise-Support-2
)	I-Premise-Support-2
,	I-Premise-Support-2
estreñimiento	I-Premise-Support-2
(	I-Premise-Support-2
39,2	I-Premise-Support-2
%	I-Premise-Support-2
frente	I-Premise-Support-2
a	I-Premise-Support-2
11,7	I-Premise-Support-2
%	I-Premise-Support-2
)	I-Premise-Support-2
,	I-Premise-Support-2
fatiga	I-Premise-Support-2
(	I-Premise-Support-2
36,6	I-Premise-Support-2
%	I-Premise-Support-2
frente	I-Premise-Support-2
a	I-Premise-Support-2
33,9	I-Premise-Support-2
%	I-Premise-Support-2
)	I-Premise-Support-2
,	I-Premise-Support-2
reacción	I-Premise-Support-2
en	I-Premise-Support-2
el	I-Premise-Support-2
lugar	I-Premise-Support-2
de	I-Premise-Support-2
la	I-Premise-Support-2
inyección	I-Premise-Support-2
(	I-Premise-Support-2
31,9	I-Premise-Support-2
%	I-Premise-Support-2
frente	I-Premise-Support-2
a	I-Premise-Support-2
0,7	I-Premise-Support-2
%	I-Premise-Support-2
)	I-Premise-Support-2
,	I-Premise-Support-2
náuseas	I-Premise-Support-2
(	I-Premise-Support-2
26,7	I-Premise-Support-2
%	I-Premise-Support-2
frente	I-Premise-Support-2
a	I-Premise-Support-2
23,7	I-Premise-Support-2
%	I-Premise-Support-2
)	I-Premise-Support-2
,	I-Premise-Support-2
vómitos	I-Premise-Support-2
(	I-Premise-Support-2
23,8	I-Premise-Support-2
%	I-Premise-Support-2
frente	I-Premise-Support-2
a	I-Premise-Support-2
14,2	I-Premise-Support-2
%	I-Premise-Support-2
)	I-Premise-Support-2
,	I-Premise-Support-2
alopecia	I-Premise-Support-2
(	I-Premise-Support-2
19,8	I-Premise-Support-2
%	I-Premise-Support-2
frente	I-Premise-Support-2
a	I-Premise-Support-2
35,4	I-Premise-Support-2
%	I-Premise-Support-2
)	I-Premise-Support-2
,	I-Premise-Support-2
estomatis	I-Premise-Support-2
(	I-Premise-Support-2
19,4	I-Premise-Support-2
%	I-Premise-Support-2
frente	I-Premise-Support-2
a	I-Premise-Support-2
12,4	I-Premise-Support-2
%	I-Premise-Support-2
)	I-Premise-Support-2
,	I-Premise-Support-2
dolor	I-Premise-Support-2
abdominal	I-Premise-Support-2
(	I-Premise-Support-2
20,1	I-Premise-Support-2
%	I-Premise-Support-2
frente	I-Premise-Support-2
a	I-Premise-Support-2
3,6	I-Premise-Support-2
%	I-Premise-Support-2
)	I-Premise-Support-2
,	I-Premise-Support-2
mialgia	I-Premise-Support-2
(	I-Premise-Support-2
14,7	I-Premise-Support-2
%	I-Premise-Support-2
frente	I-Premise-Support-2
a	I-Premise-Support-2
6,6	I-Premise-Support-2
%	I-Premise-Support-2
)	I-Premise-Support-2
,	I-Premise-Support-2
neuropatía	I-Premise-Support-2
periférica	I-Premise-Support-2
(	I-Premise-Support-2
10,7	I-Premise-Support-2
%	I-Premise-Support-2
frente	I-Premise-Support-2
a	I-Premise-Support-2
15,0	I-Premise-Support-2
%	I-Premise-Support-2
)	I-Premise-Support-2
,	I-Premise-Support-2
artralgia	I-Premise-Support-2
(	I-Premise-Support-2
7,0	I-Premise-Support-2
%	I-Premise-Support-2
frente	I-Premise-Support-2
a	I-Premise-Support-2
7,7	I-Premise-Support-2
%	I-Premise-Support-2
)	I-Premise-Support-2
,	I-Premise-Support-2
diarrea	I-Premise-Support-2
(	I-Premise-Support-2
6,2	I-Premise-Support-2
%	I-Premise-Support-2
frente	I-Premise-Support-2
a	I-Premise-Support-2
12,4	I-Premise-Support-2
%	I-Premise-Support-2
)	I-Premise-Support-2
,	I-Premise-Support-2
edema	I-Premise-Support-2
(	I-Premise-Support-2
1,5	I-Premise-Support-2
%	I-Premise-Support-2
frente	I-Premise-Support-2
a	I-Premise-Support-2
5,4	I-Premise-Support-2
%	I-Premise-Support-2
)	I-Premise-Support-2
y	I-Premise-Support-2
trastornos	I-Premise-Support-2
de	I-Premise-Support-2
las	I-Premise-Support-2
uñas	I-Premise-Support-2
(	I-Premise-Support-2
1,1	I-Premise-Support-2
%	I-Premise-Support-2
frente	I-Premise-Support-2
a	I-Premise-Support-2
5	I-Premise-Support-2
;	I-Premise-Support-2
1	I-Premise-Support-2
%	I-Premise-Support-2
)	I-Premise-Support-2
.	I-Premise-Support-2

Este	B-Claim-Support-3
estudio	I-Claim-Support-3
de	I-Claim-Support-3
fase	I-Claim-Support-3
III	I-Claim-Support-3
de	I-Claim-Support-3
no	I-Claim-Support-3
inferioridad	I-Claim-Support-3
mostró	I-Claim-Support-3
puntos	I-Claim-Support-3
finales	I-Claim-Support-3
de	I-Claim-Support-3
eficacia	I-Claim-Support-3
similares	I-Claim-Support-3
para	I-Claim-Support-3
vinflunina	I-Claim-Support-3
y	I-Claim-Support-3
docetaxel	I-Claim-Support-3
.	I-Claim-Support-3

A	O
pesar	B-Claim-Partial_Attack-1
de	I-Claim-Partial_Attack-1
las	I-Claim-Partial_Attack-1
tasas	I-Claim-Partial_Attack-1
más	I-Claim-Partial_Attack-1
altas	I-Claim-Partial_Attack-1
de	I-Claim-Partial_Attack-1
algunos	I-Claim-Partial_Attack-1
efectos	I-Claim-Partial_Attack-1
adversos	I-Claim-Partial_Attack-1
(	I-Claim-Partial_Attack-1
anemia	I-Claim-Partial_Attack-1
,	I-Claim-Partial_Attack-1
dolor	I-Claim-Partial_Attack-1
abdominal	I-Claim-Partial_Attack-1
,	I-Claim-Partial_Attack-1
estreñimiento	I-Claim-Partial_Attack-1
,	I-Claim-Partial_Attack-1
fatiga	I-Claim-Partial_Attack-1
)	I-Claim-Partial_Attack-1
,	O
el	B-Claim-Support-1
perfil	I-Claim-Support-1
de	I-Claim-Support-1
toxicidad	I-Claim-Support-1
general	I-Claim-Support-1
de	I-Claim-Support-1
la	I-Claim-Support-1
vinflunina	I-Claim-Support-1
fue	I-Claim-Support-1
manejable	I-Claim-Support-1
.	I-Claim-Support-1

Por	O
lo	O
tanto	O
,	O
VFL	B-MajorClaim
puede	I-MajorClaim
ser	I-MajorClaim
otra	I-MajorClaim
opción	I-MajorClaim
en	I-MajorClaim
el	I-MajorClaim
tratamiento	I-MajorClaim
de	I-MajorClaim
segunda	I-MajorClaim
línea	I-MajorClaim
de	I-MajorClaim
pacientes	I-MajorClaim
con	I-MajorClaim
NSCLC	I-MajorClaim
avanzado	I-MajorClaim
.	I-MajorClaim

